Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess

D. Pérez, A. Tincani, M. Serrano, Y. Shoenfeld, A. Serrano

Research output: Contribution to journalArticlepeer-review

Abstract

IgA anti-beta2-glycoprotein I (IgA-aB2GPI) antibodies are currently not included as a laboratory criterion of antiphospholipid syndrome (APS). In the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, (USA) in 2010, these antibodies were accepted as an APS laboratory criterion in patients who had clinical manifestations of APS but were negative for “consensus” antiphospholipid antibodies (aPL) (IgG and IgM isotypes). Consequently, individuals with thrombotic events who are negative for consensus aPL may be undiagnosed for APS. The most recent publications have confirmed that IgA-aB2GPI antibodies are a risk factor for thrombotic events. In this viewpoint, we propose that IgA-aB2GPI antibodies should be included as an APS consensus criterion and that we have to help Cinderella become a princess.

Original languageEnglish
Pages (from-to)177-178
Number of pages2
JournalLupus
Volume27
Issue number2
DOIs
StatePublished - 1 Feb 2018
Externally publishedYes

Keywords

  • APS
  • Anti-B2GPI
  • IgA
  • antiphospholipid antibodies
  • laboratory criteria
  • thrombosis

Fingerprint

Dive into the research topics of 'Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess'. Together they form a unique fingerprint.

Cite this